Výsledky vyhledávání - "Sara K. Guster"

Rituximab and 17-allylamino-17-demethoxygeldanamycin induce synergistic apoptosis in B-cell chronic lymphocytic leukaemia

Autor: Lisa L. Smith, Amy J. Wagner, David M. Lucas, Sara K. Guster, Thomas S. Lin, John C. Byrd, Michael R. Grever, Amy J. Johnson, Carolyn Cheney

Publikováno v: British Journal of Haematology. 139:837-844

Treatment options for chronic lymphocytic leukaemia (CLL) are limited and eventually fail because of the development of toxicities or drug resistance. Thus, identification of new therapeutic strategies and targets is a high priority. The semisyntheti

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3d6e74a3f0c6725109afaa084a364972
https://doi.org/10.1111/j.1365-2141.2007.06878.x

Zobrazit plný text záznamu

Alemtuzumab induces caspase-independent cell death in human chronic lymphocytic leukemia cells through a lipid raft-dependent mechanism

Autor: Charles F. Eisenbeis, Donn C. Young, Amy Banks, John C. Byrd, T. S. Lin, Andrew P. Mone, Carolyn Cheney, Sara K. Guster, Susheela Tridandapani, Najma Mehter

Publikováno v: Leukemia. 20:272-279

Alemtuzumab is a humanized IgG1 kappa antibody directed against CD52, a glycosyl-phosphatidylinositol linked cell-membrane protein of unknown function. Herein, we demonstrate that alemtuzumab promotes rapid death of chronic lymphocytic leukemia (CLL)

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::42de0171dcd5021e9a064d46615df912
https://doi.org/10.1038/sj.leu.2404014

Zobrazit plný text záznamu

A Phase I/II Dose Escalation Study of Apolizumab (Hu1D10) Using a Stepped Up Dosing Schedule in Patients with Chronic Lymphocytic Leukemia (CLL) and Acute Leukemia

Autor: Carolyn Cheney, Wendy Stock, Huiping Xu, Mitch A. Phelps, Bruce R. Briggs, Sara K. Guster, Thomas S. Lin, Margaret S. Lucas, John C. Byrd, Ian W. Flinn, James T. Dalton, Pierluigi Porcu, Michael R. Grever

Publikováno v: Leuk Lymphoma

Apolizumab (Hu1D10), a humanized monoclonal anti- Human leukocyte antigen -DR beta-chain antibody, mediates apoptosis of chronic lymphocytic leukemia (CLL) cells in vitro. We conducted a phase I/II dose-escalation study of thrice-weekly apolizumab (1

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::de294cc29a36cc33dac195afe27556ff
https://europepmc.org/articles/PMC8166408/

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání